Condition:   Kidney Transplant
Interventions:   Drug: Tacrolimus Withdrawal +MMF +Prednisone;   Drug: MMF/Tacrolimus/Prednisone
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012

Condition:   Kidney Transplantation
Interventions:   Drug: Alemtuzumab induction; MMF + Tacrolimus maintenance;   Drug: Alemtuzumab induction; MMF + Belatacept maintenance;   Drug: Basiliximab induction; Short-term (3 months)Tacrolimus; MMF + Belatacept maintenance
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Condition:   Kidney Transplant Rejection
Interventions:   Drug: everolimus;   Drug: cyclosporine
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified April 2012

Condition:   CNI Side Effects
Interventions:   Drug: Cyclosporine & Cellcept;   Drug: Prograf & Cellcept;   Drug: Cyclosporine, Cellcept, & Prednisone;   Drug: Prograf, Cellcept, & Prednisone;   Drug: Low Dose CNI (Cyclosporine or FK) and Cellcept;   Drug: Rapamune and Cellcept;   Drug: Low dose CNI (CSA or FK), Rapamune, & Prednisone;   Drug: Rapamune, Cellcept, & Prednisone
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   Roche Pharma AG;   Wyeth is now a wholly owned subsidiary of Pfizer;   Genzyme
Recruiting - verified April 2012

Condition:   Kidney Transplantation
Interventions:   Drug: Mycophenolic Acid;   Drug: Standard of Care: CNI and MPA
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison
Recruiting - verified November 2011